Epigenetics and Cancer: DNA Methylation

Epigenetics in Biology and Medicine

Volumn , Issue , 2008, Pages 3-16

  Ropero, Santiago ^a   Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449140705     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (65)

1. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-213.
2. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat. Rev. Genet. 2000; 1: 11-19.
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998; 72: 141-196.
4. Avner P, Heard E. X-chromosome inactivation: counting, choice and initiation. Nat. Rev. Genet. 2001; 2 (1): 59-67.
5. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 1999; 19: 7327-7335.
6. Torre L, Lopez-Rodas G, Latasa MU, Carretero MV, Boukaba A, Rodriguez JL. DNA methylation and histone acetylation of rat methionine adenosyltransferase 1A and 2A genes is tissue-specific. Int. J. Biochem. Cell. Biol. 2000; 32: 397-404.
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007; 8(4): 286-298.
8. Lapeyre JN, Becker FF. 5-methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem. Biophys. Res. Comm. 1979; 87: 698-705.
9. Ehrlich M. DNA hypomethylation and cancer. In: DNA alterations in cancer: genetic and epigenetic changes. Melanie Ehrlich, Ed., Eaton, Natick, 2000. Pp. 273-291.
10. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004; 64: 5527-5534.
11. Whitelaw E, Martin DI. Retrotransposons as epigenetic mediators of phenotypic variation in mammals. Nat. Genet. 2001; 27: 361-365.
12. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, Hulten M, Qu X, Russo JJ, Viegas-Péquignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402(6758): 187-191.
13. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1999; 301: 89-92.
14. Ropero S, Setien F, Espada J, Fraga MF, Herranz M, Asp J et al. Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. Hum. Mol. Genet. 2004; 13: 2753-2765.
15. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF et al. Epigenetic inac-tivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. USA 2006; 103: 8822-8827.
16. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004; 23: 1-8.
17. Esteller M., Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61: 3225-3229.
18. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000; 24: 132-138.
19. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedelfank I, Godwin AK et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 2001; 10: 3001-3007.
20. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedelfank I, Godwin AK et al. Hum. Mol. Genet. 2001b; 10: 3001-3007.
21. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 2007; 16 (1): R50-R59.
22. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295:1079-1082.
23. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, et al. Cancer epigenetics and methylation. Science 2002; 297: 1807-1808.
24. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
25. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J et al. Poly-comb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2006; 39: 232-236.
26. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004; 5: 522-531.
27. Miska EA. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. 2005; 5: 563-568.
28. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
29. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006; 6: 857-866.
30. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443.
31. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007; 67: 1424-1429.
32. Laird PW. Oncogenic mechanism mediated by DNA methylation. Mol. Med. Today 1997; 3: 223-229.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996; 93: 9821-9826.
34. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002; 632: 636-649.
35. Jerónimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Nat. Cancer Inst. 2001; 93(22): 1747-1752.
36. Cairns P. Gene methylation and early detection of genitourinary cancer. Nat. Rev. Cancer 2007; 7: 531-543.
37. Ahrendt SA, Chow JT, Xu L, Yang SC, Eisenberger CF, Esteller M et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Nat. Cancer Inst. 1999; 91: 332-339.
38. Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin. Cancer Res. 1999; 5: 2450-2454.
39. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004; 4 (9): 707-717.
40. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 2001; 7: 2727-2730.
41. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000; 60: 5941-5945.
42. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001; 357: 1335-1336.
43. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001; 61: 939-942.
44. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: A tool for early detection, diagnostics, and follow-up? Lung Cancer 2005; 49 (1): 1-12.
45. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M. Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet 2004; 363(9417): 1283-1285.
46. Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer: Implications for screening and pathological utility. Ann. N.Y. Acad. Sci. 2003; 983: 251-267.
47. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999; 59: 67-70.
48. Lofton-Day C, Model F, Tetzner R, DeVos T, Schuster M, Lesche R, Sledziewski A, Day RW. A real-time PCR test for septin 9 gene methylation identifies early stage colorectal cancer in plasma. Proc. Am. Assoc. Cancer Res. 2006; 47: LB-224.
49. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 629-656.
50. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Nat. Cancer. Inst. 2000; 92: 1511-1516.
51. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 alterations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 2001c; 19: 299-304.
52. Lesche R, Eckhardt F. DNA methylation markers: a versatile diagnostic tool for routine clinical use. Curr. Opin. Mol. Ther. 2006; 9: 222-230.
53. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999b; 59: 793-797.
54. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Activity of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl. J. Med. 2000a; 343: 1350-1354.
55. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primarygliomas. Clin. Cancer Res. 2004; 10(15): 4933-4938.
56. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B. Apop-tosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2006; 26(2): 186-197.
57. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5 fluorouracil in colorectal cancer cell lines. Int. J. Cancer 2003; 106 (1): 66-73.
58. Tew KD, Ronai Z. GST function in drug and stress response. Drug Resist. Updat. 1999; 2: 143-147.
59. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20: 6597-6606.
60. Villar-Garea A, Esteller M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why. Curr. Drug. Metabol. 2003; 4: 11-31.
61. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463.
62. Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes, Nat. Clin. Pract. Oncol. 2005; 2 (Suppl. 1): S36-S44.
63. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes, Clin. Cancer Res. 2005; 11: 3604-3608.
64. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J. Clin. Oncol. 2005; 23: 3906-3911.
65. Gore SD. Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate [abstract]. Blood 2004; 104: 469.